ISIS 104838

Drug Profile

ISIS 104838

Alternative Names: TNF-alpha antisense inhibitor - Isis; TNF-alpha inhibitor - Isis; Tumour necrosis factor-alpha inhibitor - Isis

Latest Information Update: 03 Mar 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Class Anti-inflammatories; Antisense oligonucleotides
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Crohn's disease; Inflammation; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 03 Mar 2005 Discontinued - Phase-I for Crohn's disease in USA (IV)
  • 03 Mar 2005 Discontinued - Phase-I for Crohn's disease in USA (PO)
  • 03 Mar 2005 Discontinued - Phase-I for Crohn's disease in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top